mirikizumab UC
Selected indexed studies
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (Gastroenterology, 2024) [PMID:39572132]
- Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. (Clin Gastroenterol Hepatol, 2025) [PMID:39147217]
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. (Gastroenterology, 2024) [PMID:39425738]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (2024) pubmed
- Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. (2025) pubmed
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. (2024) pubmed
- Mirikizumab: First Approval. (2023) pubmed
- Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. (2025) pubmed
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. (2020) pubmed
- Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme. (2024) pubmed
- An evaluation of mirikizumab for the treatment of ulcerative colitis. (2024) pubmed
- Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies. (2024) pubmed
- Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy? (2026) pubmed